Facing an extended drought of options, patients with type 3 Gaucher disease (GD3) are getting a new treatment that's also the first to address the disease's debilitating neurological effects.
The therapy comes courtesy of Sanofi, which picked up FDA approval this week for its oral glucosylceramide synthase inhibitor (GCSi) Infilbray, also known as venglustat. The drug acts across the blood-brain barrier to improve the neurologic manifestations of GD3, which include cognitive deficits and coordination and balance issues.
A rare and potentially fatal lysosomal storage disease, GD3 is caused by a defective enzyme that allows molecules called glycosphingolipids to build up in the cells of the body. For decades, clinicians have been able to treat the systemic features of the disease—like enlarged spleen and liver, anemia, easy bruising and bone pain—with enzyme replacement therapy (ERT). But none of the ERTs on tap, including Sanofi market leader Cerezyme, address the neurological decline that accompanies GD3.
“The availability of a medicine capable of addressing the neurological manifestations of this devastating disorder represents a major milestone for patients, families, and the global Type 3 Gaucher disease community,” Pramod Mistry, Ph.D., director of the Yale Lysosomal Disease Center and Gaucher Disease Treatment Center, said in Sanofi's release.
The FDA based its approval on Sanofi’s phase 3 Leap2Mono trial, which compared daily oral Infilbray to bi-weekly ERT in patients ages 12 years and up who had stabilized the systemic manifestations of their GD3 with ERT.
Patients were evaluated using modified SARA score, a validated measure of walk, balance and speech, as well as with RBAN scores, a validated metric for cognitive function. Infilbray significantly improved scores on both metrics at one year of treatment, Sanofi said in a Nov. 18 release.
“With Infilbray, we are delivering a breakthrough in care by addressing the neurological symptoms of Type 3 Gaucher disease, a milestone which reflects our deep commitment to innovation for patients and is made possible by our dedicated team who work to address their unmet medical needs,” Manuela Buxo, EVP and global head of specialty care at Sanofi, said in a statement.
The newly approved Infilbray does carry three warnings and precautions on its label for suicidal ideation and behavior, lens opacification in pediatric patients and embryofetal toxicity. The most common adverse events reported in patients on Infilbray in the study were diarrhea, spleen enlargement, nausea, depression, gastroenteritis and vomiting.
Sanofi is already the heavyweight in GD3 treatment. Cerezyme, the drugmaker's ERT, is currently the market leader, scooping up 695 million euros in 2025. With the new green light, Sanofi moves to further solidify that leadership in GD3 with the ability to offer patients relief from both the systemic and neurological manifestations of their disease.
Infilbray’s regulatory clearance in the U.S. was propelled by breakthrough designation, a rare pediatric designation, orphan designation and a fast-track designation from the FDA. The drug also has orphan status in the European Union and Japan, where it is currently under review.
Acquired as part of Sanofi's Genzyme buyout in 2011, venglustat hasn't had an easy path to approval by any stretch, though the GD3 nod now offers the medicine a shot at redemption.
Back in February when it issued results from Leap2Mono, Sanofi also reported that the drug had missed in a phase 3 study of 122 patients with another rare lysosomal storage disorder, Fabry disease. The trial, dubbed Peridot, missed its primary endpoint of showing superiority in patient-reported improvement of symptoms like neuropathic pain in upper and lower extremities, as well as abdominal pain, versus placebo.
While Sanofi's Fabry ambitions for the asset aren't ended, venglustat has otherwise had a mixed track record in the clinic, with reality checks in conditions like Parkinson's coming as far back as 2021.